Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Jul 29, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$20.5B
sum of reported positions
Reported positions
531
Changes vs prior quarter
432
75 new · 46 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 131 measured positions in 8 quarters, the typical new or larger position finished −4.2 pts against the S&P 500 and 46% finished ahead of it.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $14.7B | $20.5B |
| Positions | 502 | 531 |
| Biggest line | — | TEVA PHARMACEUTICAL INDS LTD 8% |
| 2.72M |
| $786M |
| 3.8% |
| 1.39M | $662M | 3.2% |
| 1.7M | $632M | 3.1% |
SELECT SECTOR SPDR TR | 3.24M | $599M | 2.9% |
| 2.28M | $594M | 2.9% |
SELECT SECTOR SPDR TR | 3.63M | $577M | 2.8% |
| 2.24M | $533M | 2.6% |
GLOBAL X FDS | 8.94M | $527M | 2.6% |
ISHARES TR | 743K | $476M | 2.3% |
| 836K | $471M | 2.3% |
| 1.47M | $442M | 2.2% |
GLOBAL X FDS | 6.99M | $418M | 2.0% |
| 371K | $375M | 1.8% |
| 986K | $373M | 1.8% |
| 2.23M | $363M | 1.8% |
| 300K | $353M | 1.7% |
ISHARES TR | 2.11M | $332M | 1.6% |
| 1.31M | $313M | 1.5% |
VANGUARD WORLD FD | 2.42M | $289M | 1.4% |
| 1.08M | $276M | 1.3% |
SELECT SECTOR SPDR TR | 1.4M | $266M | 1.3% |
Fox Corporation (Class A) (FOXA)
2,300 shares
Cerebras Systems (CBRS)
540 shares
Canopy Growth (CGC)
99K shares
Charles Schwab Corporation (SCHW)
1,000 shares
D. R. Horton (DHI)
550 shares
Performance Food Group (PFGC)
740 shares
Jones Lang LaSalle (JLL)
250 shares
Becton Dickinson (BDX)
480 shares
SPROTT ASSET MANAGEMENT LP
1,800 shares
ETF SER SOLUTIONS
400 shares
Avery Dennison (AVY)
350 shares
Beam Therapeutics (BEAM)
1,550 shares
Penguin Solutions, Inc. (PENG)
550 shares
ISHARES TR
547 shares
VANGUARD SCOTTSDALE FDS
324 shares
Ondas (ONDS)
3,200 shares
Navitas Semiconductor (NVTS)
1,340 shares
GLOBAL X FDS
250 shares
FedEx Freight (FDXF)
94 shares
EQT Corporation (EQT)
215 shares
SPDR GOLD TR
24 shares
Versant Media Group, Inc. (VSNT)
18 shares
Solstice Advanced Materials (SOLS)
15 shares
SPDR SERIES TRUST
1 shares
NEUBERGER BERMAN ETF TRUST
1 shares
In its latest 13F, with holdings as of Jun 30, 2026 (Q2 2026), Harel Insurance Investments & Financial Services Ltd. reported 531 positions worth $20.5B. The largest: TEVA PHARMACEUTICAL INDS LTD, 8.0%; Nova (NVMI), 5.6%; Alphabet (GOOGL), 4.6%; NVIDIA (NVDA), 4.3%; Apple (AAPL), 3.8%. The five largest make up 26% of the reported portfolio.
TEVA PHARMACEUTICAL INDS LTD: $1.63B, or 8.0% of the portfolio reported for Q2 2026.
Between its last two 13F reports, Harel Insurance Investments & Financial Services Ltd. opened 75 new positions, added to 186, trimmed 125 and sold out of 46. The comparison is in share counts, so a price move alone does not count as buying or selling.
Its 13F for Q2 2026 adds up to $20.5B. That is not the whole firm: a 13F lists only US-listed shares and some options held at the end of the quarter, and leaves out cash, bonds, short positions and foreign holdings.
The report for Q2 2026 was filed on Jul 29, 2026. A manager has 45 days after the end of each quarter to file, so the holdings are always several weeks old when they become public.
On 131 positions it reported as new or larger over 8 quarters, the typical one finished −4.2 points against the S&P 500 after 90 days, and 46% finished ahead of it. Measured from the day each filing became public; history, not a forecast.
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.